Biotech Values

[DewDiligence]

IIRC a previous wAMD drug which submitted for [FDA] approval ended up getting approved for a single dose. No continued dosing because continued dosing had unacceptable side effects.

You may be thinking of Visudyne, the first drug approved for wet AMD that is now a niche product. The FDA label permits Visudyne redosing only after an evaluation by fluorescein angiography at three months or later. The label also recommends that the initial treatment be for one eye only until safety can be assessed.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021119s034lbl.pdf